PianZiHuang

According to statistics, as of December 29, 2023, the number of listed companies in China's pharmaceutical industry reached 308, with 9 new companies listed in 2023. The total market value of pharmaceutical industry listed companies in 2023 was 462,929.3 billion yuan, down 988.98 billion yuan from 2022. There were 5 companies with market capitalization exceeding 100 billion yuan, namely, Hengrui Pharmaceuticals, Wuxi AppTec, BeiGene, ZhiFei Biological and Pianzi Hui. So, what is the current market capitalization of these 5 companies?   As of the closing on August 15, 2024, the total market capitalization of Hengrui Pharmaceuticals was 27.94 billion yuan, down 91.22 billion yuan from the end of 2023. The company is a specialized enterprise focusing on drug research, production, and sales, with its business mainly concentrated in the pharmaceutical manufacturing industry, especially in the research and sales of innovative drugs. Through cooperation with numerous enterprises and research institutions around the world, Hengrui Pharmaceuticals has achieved the overseas authorization of a number of innovative drugs, including Carvyli珠单抗， Pyrrolopyrimidine, and HRS-1167, showcasing its competitiveness and innovation capabilities in the international market.   The current total market capitalization of Wuxi AppTec is 11.64 billion yuan, down nearly 100 billion yuan from the end of 2023. The company is a comprehensive pharmaceutical R&D service provider, dedicated to advancing the drug R&D process and production services, providing breakthrough treatment solutions for patients. In the first half of this year, Wuxi AppTec achieved a revenue of 1.724 billion yuan, down 8.64% from the same period last year. Net profit attributable to the listed shareholders of BeiGene was 4.24 billion yuan, down 20.20% year-on-year.   The total market value of BeiGene was 20.06 billion yuan, up 123.69 billion yuan from the end of 2023. BeiGene is a global innovative pharmaceutical company specializing in the research and development of cancer drugs, although it has lost money for seven consecutive years, but the loss in the first half of this year has decreased. This is mainly due to the growth of product revenue, especially the sales of independently developed products BeiGene (brand name: Zebubaitini capsules) and BeiZhan (Taili Lizhuzhu injection) and the strong sales growth of Anjin authorized products. In particular, the global sales of BeiGene in the first half of the year were 80.18 billion yuan, up 122% year-on-year.   The market value of ZhiFei Biological was 5.87 billion yuan, down more than 900 billion yuan from the end of 2023. The company is an international, full-chain biotechnology enterprise integrating vaccine, biological product research, production, sales, distribution and import and export. As the domestic agent of Merck's HPV vaccine, ZhiFei Biological's revenue in the first half of the year was 4.727 billion US dollars, up 7% from last year. Merck said that 60%-70% of its HPV vaccine sales come from China, but its sales growth in the first half of the year was lower than in the past, mainly because the sales in the Chinese market decreased. As a result, Zhifei Biological achieved revenue of 11.396 billion yuan in the first quarter of this year, up by only 2%, and net profit of 1.458 billion yuan, down by 28.26%.   The current market value of Pianzihuang is 12.515 billion yuan, down by about 200 billion yuan from the end of 2023. The company's main businesses include pharmaceutical manufacturing, pharmaceutical distribution, and cosmetics, with "Pianzihuang" as its main product, covering liver disease drugs, cold and flu drugs, and dermatological drugs in multiple fields. The interim report for the first half of 2024 shows that the company's revenue for the period was about 5.65 billion yuan, up by 11.99%; net profit attributable to shareholders of the parent company was about 1.72 billion yuan, up by 11.61%. Accordingly, the company's net profit attributable to shareholders of the parent company in the second quarter was about 745 million yuan, down from the same period last year.

编者按：本文来自米内网，作者玲珑；赛柏蓝转载，编辑相宜 据国家药监局公告，2024上半年共有7个中成药获批首家或继续给予中药二级保护，32个中成药申请品种保护获受理。 01 7个中成药获保护 山东新时代、佐力药业突围 2024上半年国家药监局共发布了5个获批首家中药二级保护或延长中药保护的公告，涉及7个中成药，其中有6个为独家品种（含独家剂型）。 5个独家中成药获批为首家中药二级保护品种，分别为重庆华森制药的八味芪龙颗粒、贵州百灵的银丹心脑通软胶囊、山东新时代药业的榆栀止血颗粒、黑龙江省济仁药业的菖麻熄风片及浙江佐力药业的灵泽片。数据显示，上述5个中成药2023年在中国三大终端六大市场的销售额超过17亿元。 2024H1获批为首家中药二级保护的品种注：低于1亿元用*代替 银丹心脑通软胶囊为全国医保乙类、全国基药品种，具有活血化瘀、行气止痛、消食化滞的功效，适用于气滞血瘀引起的胸痹，症见胸痛，胸闷，气短，心悸等。 目前国内仅贵州百灵拥有银丹心脑通软胶囊生产批文，该产品近年来在中国三大终端六大市场的销售额逐年上涨，2019年首次突破10亿元，2023年超过14亿元，同比增长约6%。从终端销售看，院内市场（公立医院+公立基层医疗）为其销售主渠道，2023年在心血管系统中成药TOP10品牌中，贵州百灵的银丹心脑通软胶囊位列第七。 近年来中国三大终端六大市场银丹心脑通软胶囊销售情况（单位：万元） 灵泽片为全国医保乙类、国家基药品种，具有益肾活血、散结利水的功效，适用于良性前列腺增生（肾虚血瘀湿阻证）出现的尿频，排尿困难，尿线变细，淋漓不尽，腰膝酸软等。灵泽片为浙江佐力药业独家品种，近年来在中国三大终端六大市场的销售额持续快速增长，2023年超过1.5亿元，同比增长约23%。 近年来中国三大终端六大市场灵泽片销售情况（单位：万元） 2个中成药获批继续予以2级保护，分别为北京汉典制药的银杏酮酯滴丸、江苏苏中药业的黄葵胶囊。 2024H1获批继续予以2级保护的中成药注：低于1亿元用*代替 黄葵胶囊为全国医保乙类品种，具有清利湿热、解毒消肿的功效，适用于慢性肾炎之湿热症，症见浮肿、腰痛，蛋白尿、血尿、舌苔黄腻等。黄葵胶囊为江苏苏中药业独家品种，近年在中国三大终端六大市场市场规模持续增长，2023年其销售额接近10亿元。其中，院内市场（公立医院+公立基层医疗）为其销售主渠道，在泌尿系统中成药TOP10产品中，黄葵胶囊位列第五。 近年来中国三大终端六大市场黄葵胶囊销售情况（单位：万元） 02 32个中成药申请保护 康缘、健民出击 2024上半年国家药监局共发布20个中药品种保护受理公示的公告，涉及32个中成药（以药品名+企业名计，31个为独家品种），其中申请初保的品种有27个，申请续保的品种有5个。 申请初保的27个中成药均为独家品种，2023年在中国三大终端六大市场的销售额合计超过36亿元，其中有7个销售额超过1亿元，包括江苏康缘药业的银杏二萜内酯葡胺注射液、贵州三力制药的开喉剑喷雾剂（儿童型）、健民药业的便通胶囊、辽宁沃华康辰医药的骨疏康胶囊等。从销售额增速看，雷允上的黄厚止泻滴丸、一品红生物的芩香清解口服液分别涨超480%、120%。 2024H1申请初保的中成药注：低于1亿元用*代替 开喉剑喷雾剂（儿童型）为全国医保乙类品种，具有清热解毒、消肿止痛的功效，适用于急慢性咽喉炎，扁桃体炎，咽喉肿痛，牙龈肿痛等。开喉剑喷雾剂（儿童型）为贵州三力制药独家品种，近年来中国三大终端六大市场的销售额均以两位数的增速持续增长，2023年超过12亿元，其中院内市场（公立医院+公立基层医疗）为其销售主渠道，在儿科中成药TOP10产品中，开喉剑喷雾剂（儿童型）位列第二，较2022年提升1个位次。 近年来中国三大终端六大市场开喉剑喷雾剂（儿童型）销售情况（单位：万元） 申请续保的5个中成药2023年在中国三大终端六大市场的销售额合计超过25亿元，其中有3个销售额超过1亿元，包括漳州片仔癀药业的片仔癀（锭剂）、西安碑林药业的和血明目片及广州诺金制药的百合固金片。 2024H1申请续保的中成药注：低于1亿元用*代替 漳州片仔癀药业的片仔癀（锭剂）为OTC甲类（双跨）品种，具有清热解毒、凉血化瘀、消肿止痛等功效。数据显示，近年来片仔癀（锭剂）在中国三大终端六大市场的销售额逐年上涨，2023年超过20亿元，其中城市实体药店为其销售主渠道，在肝病中成药TOP10产品中，片仔癀（锭剂）稳居首位。 近年来中国三大终端六大市场片仔癀（锭剂）销售情况（单位：万元） 片仔癀药业自2003年6月上市以来，始终依靠中药保护品种片仔癀（锭剂）实现业绩和市值的增长。2023年其营业收入100.6亿元（+15.69%），归母净利润达到27.97亿元（+13.15%）；2024第一季度其营业收入与归母净利润均实现两位数的稳增长。片仔癀市值长期高居A股中药板块第一位，也是目前该板块中唯一一家市值超过千亿元的上市公司。 资料来源：米内网数据库、国家药监局官网等 END 内容沟通：郑瑶（13810174402） 医药代理商产品交流群 扫描下方二维码加入 医药代表交流群 扫描下方二维码加入 左下角「关注账号」，右下角「在看」，防止失联